Corporate | 31 March 2011 07:00

United States Army and Cytos Biotechnology Collaborate on Malaria Vaccines Research

Cytos Biotechnology AG / Key word(s): Alliance

31.03.2011 / 07:00

Schlieren (Zurich), Switzerland, March 31, 2011 – Cytos Biotechnology Ltd (SIX:CYTN) announced today that it has entered a Cooperative Research and Development Agreement (CRADA) for the preclinical development of a malaria vaccine with the Walter Reed Army Institute of Research (WRAIR). Cytos Biotechnology will provide its virus-like particle (VLP) based vaccination technology and expertise whilst WRAIR will contribute a malaria antigen candidate. Vaccine candidates generated by Cytos Biotechnology will be tested in preclinical models of malaria disease by WRAIR.

Dr Martin Bachmann, CSO of Cytos Biotechnology commented ‘The WRAIR is the largest and most diverse biomedical research laboratory in the US Department of Defense and we keenly welcome the opportunity to work with them in malaria vaccine R&D. Malaria is a major disease burden for people living in at-risk areas and it poses a significant threat to military personnel serving in such regions and to travelers. Consequently, the development of new vaccines to prevent malaria is an important area of focus for vaccine R&D. This collaboration is our second malaria vaccine partnership with leading research institutes in the United States of America following the recent announcement of our collaboration with the NIH and SAIC. This new collaboration demonstrates the continuing attractiveness of the VLP-platform for partnering in the eyes of leading biomedical organizations in academia, government agencies, and industry.’

For further information please contact:
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner@cytos.com
Website: www.cytos.com

About Malaria
More than 40 percent of the world’s population lives in areas where there is a risk of contracting malaria. Nearly one million people die of malaria every year, mostly infants, young children and pregnant women and most of them in Africa. Approximately 300-500 million cases of clinical malaria occur each year. Malaria accounts for at least $12 billion in economic losses each year in Africa, and a reduction in annual economic growth estimated at 1.3 percent. (Source: NIH Website)

About WRAIR
The Walter Reed Army Institute of Research (WRAIR) is the largest and most diverse biomedical research laboratory in the United Sates of America Department of Defense.

About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs(TM). Immunodrugs(TM) are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs(TM) are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug(TM) platform, Cytos Biotechnology has built a diversified pipeline of Immunodrug(TM) candidates in various disease areas, of which five are currently in clinical development. The Immunodrug(TM) candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Currently, the Company has 76 full-time employees. Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

This foregoing press release may contain forward-looking statements that include words or phrases such as ‘will’, ‘will be tested’, ‘candidates’, ‘intended’, ‘designed’ or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.

End of Corporate News

31.03.2011 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies.
The Swiss news archive can be found at http://www.equitystory.ch/nachrichten

Language:	English
Company:	Cytos Biotechnology AG
	Wagistr. 25
	8952 Schlieren
	Schweiz
Phone:	+41 44 733 4747
Fax:	+41 44 733 4740
E-mail:	info@cytos.com
Internet:	www.cytos.com
ISIN:	CH0011025217, CH0029060735
Swiss Security Number:	–
Listed:	Regulierter Markt in SIX; Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt

End of News EquityStory AG News-Service

117679  31.03.2011